Neoprobe leaps on US FDA acceptance of cancer diagnostic agent NDA
This article was originally published in Scrip
Executive Summary
Shares of Neoprobe jumped as high as 21%, or 55 cents, on 20 October, after the firm revealed that the US FDA accepted the company's new drug application (NDA) for its radioactive diagnostic tracing agent Lymphoseek (tilmanocept) for use in intraoperative lymphatic mapping (ILM), a surgical oncology procedure used primarily in patients with breast cancer and melanoma to determine if disease has spread to the lymph nodes.